THE ROLE OF INFECTION IN PATHOGENESIS OF ATHEROGENOUS INFLAMMATORY PROCESS
https://doi.org/10.17650/1818-8338-2013-1-9-13
Abstract
Clinical manifestations of atherosclerosis are the most significant medical, social and economic challenge of our time, distant from its decision. Research study of atherogenesis at the cellular level, communication mediators and receptor-activation reactions indirect immunocompetent cells identify pathogenetic parts of the atherosclerotic process. In this article the role of infectious agents in formation of endothelial dysfunction, development of system inflammatory response and lipid transformation of the vascular wall, underlying an atherosclerosis
is surveyed.
About the Author
O. N. PavlovRussian Federation
References
1. Bobryshev Y.V., Cherian S.M., Inder S.J. et al. Neovascular expression of VE-cadherin in human atherosclerotic arteries and its relation to intimal inflammation. Cardiovasc Res 1999;43(4):1003–17.
2. Vanderlaan P.A., Readon C.A. Thematic review series: the immune system and atherogenesis. The unusual suspects: an overview of the minor leukocyte populations in atherosclerosis. J Lipid Res 2005;46(5):829–38.
3. Steinberg D., Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation 1997;95(4):1062–71.
4. Esterbauer H., Wäg G., Puhl H. Lipid peroxidation and its role in atherosclerosis.Br Med Bull 1993;49(3):566–76.
5. Титов В.Н. Общность атеросклероза и воспаления: специфичность атеросклероза как воспалительного процесса. Роскардиол журн 1999;(5):48–56.
6. Lo Presti R., Canino B., Montana M. et al. Polymorphonuclear leukocyte integrin profile in vascular atherosclerotic disease. Clin Hemorheol Microcirc 2004;30(1):53–60.
7. Kougias P., Chai H., Lin P.H. et al. Defensins and cathelicidins: neutrophil peptides with roles in inflammation, hyperlipidemia and atherosclerosis. J Cell Mol Med 2005;9(1):3–10.
8. Оглоблина О.Г., Белова Л.А., Архаков а И.А. Биохимические и клинические аспекты участия гранулоцитов и их протеинов в поражении стенки сосудов. Тер архив 1996;68(5):78–80.
9. Danesh J., Collins R., Appleby P., Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279(18):1477–82.
10. Gurevich V.S. Influenza, autoimmunity and atherogenesis. Autoimmun Rev 2005;4(2):101–5.
11. Libby P., Egan D., Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997;96(11):4095–103.
12. Jackson L.A., Campbell L.A., Schmidt R.A. et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol 1997;150(5):1785–90.
13. Benitez M.B., Cuniberti L., Fornari M.C. et al. Endothelial and leukocyte adhesion molecules in primary hypertriglyceridemia. Atherosclerosis 2008;197(2):679–87.
14. Ball R.Y., Stowers E.C., Burton J.H. et al. Evidence that the death of macrophage foam cells contributes to the lipid core of atheroma. Atherosclerosis 1995;114(1):45–54.
15. Erkkilä A.T., Närvänen O., Lehto S. et al. Autoantibodies against oxidized lowdensity lipoproteins and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000;20(1):204–9.
16. Weiss D., Sorescu D., Taylor W.R. Angiotensin II and Atherosclerosis. Am J Cardiol 2001;87(8A):25C–32C.
17. Sagastagoitia J.D., Saez Y., Vacas M. et al. Association between inflammation, lipid and haemostatic factors in patients with stable angina. Thromb Res 2007;120(1):53–9.
18. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91(11):2844–50.
19. Matsuura E., Kobayashi K., Lopez L.R. Preventing autoimmune and infection triggered atherosclerosis for an enduring healthful lifestyle. Autoimmunity Rev 2008;7(3):214–22.
20. Kalayoglu M.V., Libby B., Byrne G.I. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 2002;288(21):2724–31.
21. Pershinka H., Mayr M., Millonig G. et al. Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23(6):1060–5.
22. Gredmark S., Tilburgs T., Soderberg Naucler C. Human cytomegalovirus inhibits cytokines-induced macrophage differentiation. J Virol 2004;78(19):10378–89.
23. Панченко Е.П. Механизмы развития острого коронарного синдрома. Рус мед журн 2000;8(8):359–64.
24. Tiirola T., Sinisalo J., Nieminen M.S. et al. Chlamydial lipopolysaccharide is present in serum during acute coronary syndrome and correlates with CRP levels. Atherosclerosis 2007;194(2):403–7. Epub
25. Sep 15.
26. Ахматов А.Т., Сибиряк С.В., Симбирце в А.С. Влияние рекомбинантного ИЛ-1b (беталейкина) на цитохром Р450-зависимые монооксигеназы печени крыс. Мед иммунол 2003;5(3–4):426.
27. Mazor R., Shurtz-Swirski R., Farah R. et al. Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients. Atherosclerosis
28. ;197(2):937–43.
29. Nicholson A.C. Expression of CD36 in macrophages and atherosclerosis: the role of lipid regulation of PPARgamma signaling. Trends Cardiovasc Med 2004;14(1):8–12.
30. Fulop T.Jr., Larbi A., Fortun A. et al. Elastin peptides induced oxidation of LDL by phagocytic cells. Pathol Biol (Paris) 2005;53(7):416–23.
31. Guetta E., Guetta V., Shibutani T., Epstein S.E. Monocytes harboring cytomegalovirus: interactions with endothelial cells, smooth muscle cells, and oxidized low-density lipoprotein. Possible mechanisms for activating virus delivered by monocytes to sites of vascular injury. Circ
32. Res 1997;81(1):8–16.
33. Ibrahim A.I., Obeid M.T., Jouma M.J. et al. Detection of herpes simplex virus, cytomegalovirus and Epstein-Barr virus DNA in atherosclerotic plaques and in unaffected bypass grafts. J Clin Virol
34. ;32(1):29–32.
35. Schwartz S.M., Murry C.E. Proliferation and the monoclonal origins of atherosclerotic lesions. Annu Rev Med 1998;49:437–60.
36. Grayston J.T. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 2000;181(Suppl 3):S402–10.
37. Erridge C., Stewart J., Poxton I.R. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit lipopolysaccharides signaling. J Exp Med
38. ;197(12):1787–91.
39. Takeuchi O., Kawai T., Mühlradt P.F. et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001;13(7):933–40.
40. Zhu X., Bagchi A., Zhao H. et al. Tolllike receptor 2 activation by bacterial peptidoglycan-associated lipoprotein activates cardiomyocyte inflammation and contractile dysfunction. Crit Care Med
41. ;35(3):886–92.
42. Бондаренко В.М., Лиходед В.Г. Микробный фактор и Toll-подобные рецепторы в патогенезе атеросклероза. Журн микробиол, эпидемиол и иммунобиол 2009;(6):107–12.
43. Лиходед В.Г., Бондаренко В.М., Гинцбур г А.Л. Экзогенные и эндогенные факторы в патогенезе атеросклероза. Рецепторная теория атерогенеза. Рос кардиол журн 2010;(2):92–6.
44. Воробьев А.А., Абакумова Ю.В. Роль вирусно-герпетической инфекции в развитии атеросклероза: клинические, вирусологические, иммунологические доказательства. Вестн РАМН 2003;(4):3–10.
45. Гусев Д.Е., Пономарь Е.Г. Роль С-реактивного белка и других маркеров острой фазы воспаления при атеросклерозе. Клин мед 2006;84(5):25–9.
46. Назаров П.Г. Реактанты острой фазы воспаления. СПб.: Наука, 2001.
47. Шаврин А.П., Ховаева Я.Б., Головско й Б.В. Взаимосвязи толщины комплекса интима-медиа сонных артерий с инфекционными, иммунными, метаболическими факторами и маркерами
48. воспаления у практически здоровых лиц. Клиницист 2011;(2):46–51.
49. Бондаренко В.М., Гинцбург А.Л., Лиходе д В.Г. Роль инфекционного фактора в патогенезе атеросклероза. Эпидемиол и инфекц бол 2011;(1):7–11.
50. Muhlestein J.B., Anderson J.L. Infectious serology and atherosclerosis: how burdensome is the risk? Circulation 2003;107(2):220–2.
51. Никитин Ю.П., Решетников О.В., Курилович С.А., Малютина С.К. Ишемическая болезнь сердца, хламидийная и хеликобактерная инфекция (популяционное исследование). Кардиология
52. ;(8):4–7.
53. Ieven M.M., Hoymans V.Y. Involvement of Chlamydia pneumoniae in atherosclerosis: more evidence for lack of evidence. J Clin Microbiol 2005;43(1):19–24.
54. Белобородова Н.В., Галина Д.Х., Бусленк о Н.С. Современные представления о роли инфекции в генезе атеросклероза. Тер архив 2006;78(10):85–9.
55. Demer L.L., Tintut I.V., Abedin M. Role of inflammation in atherosclerotic calcification, metaplasia and osteoporosis. Atherosclerosis XIII. Proceedings of the 13th International Atherosclerosis Symposium 2004;1262:570–3.
56. Osterud B., Bjorklid E. Role monocytes in atherogenesis. Physiol Rev 2003;83(4):1069–112.
57. Evans C.E., Mylchreesta S., Charlton Menysa V., Durrington P. The role of hydrostatic pressure in foam cell formation upon exposure of macrophages to LDL and oxidized LDL. Atherosclerosis
58. ;197(2):596–601.
59. Frostegard J. Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmun Rev 2002;1(4):233–37.
60. Harrison D., Griendling K.K., Landmesser U. et al. Role of oxidative stress in
61. atherosclerosis. Am J Card 2003;91(3):7–11.
62. Heinecke J.W. Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol 2007;91(3):12–6.
63. Głowińska B, Urban M. Selected cytokines (IL-6, IL-8, IL-10, MCP-1, TNF-alfa) in children with atherosclerosis risk factors: obesity, hypertension, diabetes (in Polish). Wiad Lek 2003;56(3–4):109–16.
64. ZhouY.J.,Wang J.H., Zhang J. Hepatocyte growth factor protects human endothelial cells against advanced glycation end products-induced apoptosis.Biochem Biophys Res Commun
65. ;344(2):658–66.
66. Larsson P.T., Hallerstam S., Rosfors S., Wallén N.Н. Circulating markers of inflammation are related to carotid artery atherosclerosis. Int Angiol 2005;24(l):43–51.
Review
For citations:
Pavlov O.N. THE ROLE OF INFECTION IN PATHOGENESIS OF ATHEROGENOUS INFLAMMATORY PROCESS. The Clinician. 2013;7(1):9-13. (In Russ.) https://doi.org/10.17650/1818-8338-2013-1-9-13